Cargando…

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer

Detalles Bibliográficos
Autores principales:	Seguin, Laetitia, Féral, Chloé
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049313/ https://www.ncbi.nlm.nih.gov/pubmed/30035160 http://dx.doi.org/10.18632/oncoscience.416

Ejemplares similares

Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
por: Seguin, Laetitia, et al.
Publicado: (2022)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

Druggable Drivers of Lung Cancer
por: Fawdar, Shameem, et al.
Publicado: (2013)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

KRAS: A Druggable Target in Colon Cancer Patients
por: Negri, Francesca, et al.
Publicado: (2022)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

The Missing Link between (Un)druggable and Degradable KRAS
por: De Vita, Elena, et al.
Publicado: (2020)

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
por: Vallejo, Adrian, et al.
Publicado: (2017)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Exploits in Medicine
Publicado: (1891)

Esophageal Adenocarcinomas: A Need for Speed Driven by Immune Pathways That Have Druggable Targets
por: Souza, Rhonda F.
Publicado: (2018)

NANOBODY(®) Molecule, a Giga Medical Tool in Nanodimensions
por: Kunz, Sarah, et al.
Publicado: (2023)

Twists and turns in Kras-driven tumor initiation
por: Maru, Yoshiaki, et al.
Publicado: (2021)

Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation
por: Mukhopadhyay, Suman, et al.
Publicado: (2015)

Rare diseases and omics-driven personalized medicine
por: Šimić, Goran
Publicado: (2019)

Exploiting cancer genomics in pet animals to gain advantage for personalized medicine decisions
por: Król, Magdalena, et al.
Publicado: (2014)

Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2019)

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
por: Liu, Huiqin, et al.
Publicado: (2022)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

Synthetic Vulnerabilities in the KRAS Pathway
por: Roman, Marta, et al.
Publicado: (2022)

Exploiting biodiversity in the marine environment: a personal perspective
por: Gutnick, David
Publicado: (2010)

Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein
por: Janssen, Kobe, et al.
Publicado: (2023)

Druggable Targets of Squamous Cell Lung Cancer
por: Kim, Cheol Hyeon
Publicado: (2013)

The Tumor Microenvironment: A Druggable Target for Metastatic Disease?
por: EBioMedicine
Publicado: (2018)

Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer
por: Choi, Stephen Y. C., et al.
Publicado: (2022)

Inducing and exploiting vulnerabilities for the treatment of liver cancer
por: Wang, Cun, et al.
Publicado: (2019)

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
por: Westcott, Peter M. K., et al.
Publicado: (2014)

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

FAP: Not Just a Biomarker but Druggable Target in Liver Fibrosis
por: Kim, Jieun, et al.
Publicado: (2023)

Iron out KRAS-driven cancer
por: Lei, Guang, et al.
Publicado: (2022)

CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer
por: Sauta, Elisabetta, et al.
Publicado: (2021)

Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking
por: Brew, Tom, et al.
Publicado: (2021)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

A metabolic vulnerability of small-cell lung cancer
por: Nomura, Miyuki, et al.
Publicado: (2018)

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

Targeting LKB1 in cancer – exposing and exploiting vulnerabilities
por: Momcilovic, M, et al.
Publicado: (2015)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

An RNA Interference Lethality Screen of the Human Druggable Genome to Identify Molecular Vulnerabilities in Epithelial Ovarian Cancer
por: Sethi, Geetika, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9qn9jq78mtj8uhpro3139jfg8l